Genia Turanova, Chief Investment Strategist for Game-Changing Stocks and Fast-Track Millionaire, is a financial writer and money manager whose experience includes serving for more than a decade as a portfolio manager and Investment Committee member for a New York-based money management firm. Genia also researched, wrote and managed recommendations for several investment advisories. From 2011 to 2016, she served as Editor of the award-winning Leeb Income Performance newsletter. Genia also wrote for The Complete Investor, another award winner, from 2003 to 2016. During that time, Genia was responsible for several portfolios, including the "Income/Value" portfolio and the "FastTrack" portfolio. Genia's academic credentials include an MBA in Finance and Investments from the Zicklin School of Business, Baruch College in New York City. Genia is a CFA Charterholder.
Analyst Articles
Carbonite (Nasdaq: CARB), a data security and protection company, reported its second-quarter 2019 financial results after Thursday’s close. While growth in the second quarter was strong (in line with expectations), the company lowered its revenue guidance for the full year to high single digits. While… Read More
Market folklore is rich with insights. “Don’t fight the tape” — a version of the “Don’t fight City Hall” sentiment — is one such example. The financial glossary on Nasdaq’s website explains this notion as follows: “Phrase advising not to trade… Read More
The market’s comeback this year is one for the record books: The S&P 500 closed the best...
Read More
The market’s comeback this year is one for the record books: The S&P 500 closed the best first half of a year since 1997. Not too many analysts predicted such a big rally — but then...
Read More
Our first foray into the world of medical and recreational cannabis over at Fast-Track Millionaire...
Read More
Our first foray into the world of medical and recreational cannabis over at Fast-Track Millionaire remains the industry leader. It was the first among the industry players to secure a large and...
Read More
Some investors may be concerned about buying stocks when the S&P 500 is up double-digits in...
Read More
Some investors may be concerned about buying stocks when the S&P 500 is up double-digits in less than six months. That’s understandable. As I write this, the S&P 500 index has rallied...
Read More
Shares of genetic testing company Myriad Genetics (Nasdaq: MYGN) bucked the overall market, rallying 7% in the last hour of trading. The reason: news that the company resolved an issue with the government regarding Medicare billing for the Company’s hereditary cancer testing from 2014 to… Read More
With U.S. stocks hitting record highs, investors face a question of where to invest. True,...
Read More
With U.S. stocks hitting record highs, investors face a question of where to invest. True, that’s always THE question — but this market isn’t an ordinary one. Expectations for...
Read More
Our cancer-focused biotech Seattle Genetics (Nasdaq: SGEN) is up more than 15% this morning. The company’s surprise revenue beat is the main reason. Tuesday after the market closed, SGEN released second-quarter results that showed as much as $159 million in revenue brought in by… Read More
The market’s comeback this year is one for the record books: The S&P 500 closed the best first half of a year since 1997. Not too many analysts predicted such a big rally — but then, not too many thought the U.S. Federal Reserve… Read More
Money is cheap and, with the Fed apparently re-embarking on an easing course, it will be getting...
Read More
Money is cheap and, with the Fed apparently re-embarking on an easing course, it will be getting even cheaper. This is a negative for your savings account. On the flip side, though, borrowing is not...
Read More
